Journal of the American Society of Hypertension
Volume 2, Issue 4, Supplement , Pages S10-S15 , July 2008

Achieving blood pressure control in clinical practice

Based on material presented at a Boehringer Ingelheim-Sponsored Meeting held in Madrid, Spain, May 4–5, 2007.

  • Bryan Williams, MD, FRCP, FAHA

      Affiliations

    • Corresponding Author InformationCorresponding author: Bryan Williams, MD, FRCP, FAHA, Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Building, Leicester Royal Infirmary, PO Box 65, Leicester LE2 7LX, United Kingdom. Tel: +44 0 116 252 3182; fax: +44 0 116 252 5847.

References 

  1. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35:539–543
  2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 2003;289:2560–2572
  3. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535
  4. Sipahi I, Tuzcu M, Schoenhagen P, Wolski KE, Nicholls SJ, Balog C, et al. Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. J Am Coll Cardiol. 2006;48:833–838
  5. Mancia G, Grassi G. Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens. 2002;20:1461–1464
  6. Arima H, Tzourio C, Butcher K, Anderson C, Bousser MG, Lees KR, et al. Prior events predict cerebrovascular and coronary outcomes in the PROGRESS trial. Stroke. 2006;37:1497–1502
  7. Williams B. Hypertension in the young: preventing the evolution of disease versus prevention of clinical events. J Am Coll Cardiol. 2007;50:840–842
  8. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of Mild Hypertension study final results. JAMA. 1993;270:713–724
  9. Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy?. Am J Hypertens. 2000;13:418–426
  10. Sharma AM, Davidson JA, Gavin JR, Desousa NJ. Comparison of the antihypertensive efficacy of telmisartan/hydrochlorothiazide vs valsartan/hydrochlorothiazide in high-risk overweight/obese patients with hypertension and type 2 diabetes. Hypertension. 2005;46:898–899
  11. Sharma AM, Davidson J, Koval S, Lacourciere Y SMOOTH Study Investigators. Telmisartan/HCTZ versus valsartan/HCTZ in obese hypertensive patients with type 2 diabetes: the SMOOTH study. Cardiovasc Diabetol. 2007;6:28
  12. NICE/BHS. Clinical guideline 34: hypertension (Management of hypertension in adults in primary care: partial update). http://www.nice.org.uk/CG034guidanceAccessed: September 26, 2007
  13. Williams B. β-blockers and the treatment of hypertension. J Hypertens. 2007;25:1351–1353
  14. Williams B. The obese hypertensive (The weight of evidence against β-blockers). Circulation. 2007;115:1973–1974
  15. Sleight P. The ONTARGET/TRANSCEND trial programme: baseline data. Acta Diabetol. 2005;42:S50–S56
  16. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, et al. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment study in ACE INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J. 2004;148:52–61
  17. Ruilope LM, Redon J, Schmieder R. Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? (Expectations from the ONTARGET trial programme). Vasc Health Risk Manag. 2007;3:9
  18. Williams B, Gosse P, Lowe L, Harper R PRISMA I Study Group. The prospective, randomized, investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J Hypertens. 2006;24:193–200
  19. Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens. 2006;24:1193–1200

 Conflict of interest: none.

PII: S1933-1711(08)00040-5

doi: 10.1016/j.jash.2008.03.009

Journal of the American Society of Hypertension
Volume 2, Issue 4, Supplement , Pages S10-S15 , July 2008

Article Tools

* Image Usage & Resolution